Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

Figures & data

Figure 1 Radiologic images, timeline and changes in the CEA level during the patient’s clinical course.

Table 1 All Detected Variants in the Patient’s Punctured Lung Tissue (July 2021)

Gene	NM.	Exon/Intron	HGVS_c.	HGVS_p.	AF/CNVs
EGFR	NM_005228.3	exon21	c. 2573T>G	p. L858R	1.32%
EGFR	NM_005228.3	exon17	c. 1934C>G	p. S645C	7.13%
ARAF	NM_001256196.1	exon7	c. 660C>A	p. N220K	13.17%
ERBB4	NM_005235.2	exon3	c. 259G>A	p. V87M	11.49%
DNMT3A	NM_175629.2	exon4	c. 327dup	p. Q110Afs*14	8.55%
PIGR	NM_002644.3	exon4	c. 651G>T	p. Q217H	8.14%
STAT5B	NM_012448.3	intron1	c. −10-10_-10-7del		3.53%
CDK8	NM_001260.2	exon13	c. 1271G>A	p. R424H	2.50%
BTG2					3.53
BTG1					3.49
RARA					3.14

Figure 2 EGFR S645C and EGFR L858R detected in lung tissue (July 2021), plasma (January 2022) and pleural fluid (January 2022).

Data Sharing Statement

The original contributions presented in this study are included in the article and further inquiries can be directed to the corresponding author.